Skip to main content
Vitrolife logo

Vitrolife — Investor Relations & Filings

Ticker · VITR ISIN · SE0011205202 LEI · 5493001WDZMONMSPPR49 ST Manufacturing
Open in API
Filings indexed 656 across all filing types
Latest filing 2009-11-18 Regulatory Filings
Country SE Sweden
Listing ST VITR

About Vitrolife

https://www.vitrolife.com/

Vitrolife is a global company focused on reproductive health, providing medical devices and genetic testing services primarily to In Vitro Fertilization (IVF) clinics. The company develops, produces, and markets a comprehensive portfolio of products and solutions that support the entire assisted reproduction treatment journey, from oocyte retrieval and sperm preparation to fertilization, embryo culture, evaluation, transfer, and cryopreservation. With a strong emphasis on quality control, innovation, and clinical support, Vitrolife aims to improve treatment outcomes and operational efficiency for its partners. The company also offers educational resources and training for professionals through its Vitrolife Academy.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is a press release dated November 18, 2009, announcing that the company (Vitrolife) received a research grant from VINNOVA for developing clinical stem cell media. This type of announcement, detailing specific operational news, research progress, or minor corporate events that don't fit into standard financial reports (like 10-K, ER, or IR), typically falls under general regulatory announcements or news releases. Since there is no specific category for 'Research Grant Announcement' and it is not a formal financial report, capital change, or management change, the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements. It is too specific for a general 'LTR' (Legal Proceedings) and does not relate to dividends (DIV), management changes (MANG), or financing (CAP). Given the nature of a press release detailing operational progress, RNS is the best fit among the provided options.
2009-11-18 Swedish
Regulatory Filings 2009
Regulatory Filings Classification · 95% confidence The document is explicitly titled 'Press Release' and announces a specific event: receiving a research grant from VINNOVA for stem-cell media development. This is a time-sensitive, non-periodic corporate announcement that does not fit the definitions for Annual Reports (10-K), Quarterly Reports (IR), Earnings Releases (ER), or specific financial/governance filings. It is a general corporate update regarding research funding and strategic direction. Since it is a press release announcing a specific, non-financial event (a grant award), it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for important, non-standard announcements, or potentially 'Capital/Financing Update' (CAP) due to the grant funding, but RNS is safer for general press releases not related to core financial reporting or capital structure changes like debt/equity issuance. Given the options, RNS serves as the most appropriate fallback for a general press release about a research grant.
2009-11-18 English
M&A Activity 2009
M&A Activity Classification · 99% confidence The document is a press release dated November 2, 2009, announcing that Vitrolife is acquiring IVF Limited and starting direct sales in the UK and Ireland. This announcement details a significant corporate transaction (acquisition/takeover of a business unit/sales channel). This fits best under the M&A Activity category (TAR), which covers merger proposals or takeover bids, even if it's an asset/business line acquisition rather than a full company merger. It is not a standard financial report (10-K, IR, ER) or a general regulatory filing (RNS), but a specific corporate action announcement.
2009-11-02 English
M&A Activity 2009
M&A Activity Classification · 99% confidence The document is titled 'Pressmeddelande' (Press Release) and announces a specific corporate action: the acquisition of IVF Limited and the start of direct sales in the UK and Ireland. This is a material event announcement concerning corporate strategy and business operations, but it does not fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or DIV (Dividend Notice). Since it is a significant, non-standard corporate announcement that doesn't fit the other specific types (like M&A, Capital Change, or Management Change), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for official regulatory announcements not covered elsewhere. The document length is short (3687 chars) and it is a direct announcement, not a report itself.
2009-11-02 Swedish
Interim / Quarterly Report 2009
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport Januari–September 2009' (Interim Report January–September 2009) for Vitrolife AB. It contains detailed financial statements, including income statements, cash flow analysis, and segment reporting for the first nine months of the fiscal year. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). 9M 2009
2009-10-26 Swedish
Interim / Quarterly Report 2009
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January–September 2009' and contains detailed financial statements, including income statements, cash flow analysis, and segment reporting for the specified period. It provides a comprehensive review of the company's performance, which fits the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, but the report itself. 9M 2009
2009-10-26 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.